Alpha Tau Medical (NASDAQ:DRTS) Stock Price Expected to Rise, LADENBURG THALM/SH SH Analyst Says

Alpha Tau Medical (NASDAQ:DRTS) had its price target hoisted by stock analysts at LADENBURG THALM/SH SH from $12.00 to $14.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. LADENBURG THALM/SH SH’s price objective would indicate a potential upside of 41.70% from the stock’s current price.

Other analysts have also recently issued research reports about the company. Piper Sandler reiterated a “neutral” rating and set a $5.00 price objective on shares of Alpha Tau Medical in a research report on Wednesday, March 4th. HC Wainwright upped their price target on Alpha Tau Medical from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday. Zacks Research upgraded Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 17th. Citigroup upped their price target on Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Monday, April 20th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $10.75.

Alpha Tau Medical Stock Down 4.4%

Shares of DRTS stock traded down $0.46 during mid-day trading on Tuesday, hitting $9.88. The company’s stock had a trading volume of 872,370 shares, compared to its average volume of 428,413. Alpha Tau Medical has a 52-week low of $2.75 and a 52-week high of $10.80. The business has a 50-day moving average price of $7.43 and a 200 day moving average price of $6.17. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.45 and a current ratio of 7.45. The stock has a market cap of $869.54 million, a price-to-earnings ratio of -18.64 and a beta of 1.11.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Research analysts predict that Alpha Tau Medical will post -0.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Alpha Tau Medical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mariner LLC raised its position in Alpha Tau Medical by 1.6% during the fourth quarter. Mariner LLC now owns 125,165 shares of the company’s stock valued at $620,000 after purchasing an additional 1,915 shares during the period. Trifecta Capital Advisors LLC purchased a new stake in Alpha Tau Medical during the fourth quarter valued at approximately $48,000. Levin Capital Strategies L.P. raised its position in Alpha Tau Medical by 6.3% during the third quarter. Levin Capital Strategies L.P. now owns 204,714 shares of the company’s stock valued at $923,000 after purchasing an additional 12,200 shares during the period. Envestnet Asset Management Inc. purchased a new stake in Alpha Tau Medical during the third quarter valued at approximately $62,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock worth $116,000 after buying an additional 17,500 shares during the period. 2.65% of the stock is currently owned by hedge funds and other institutional investors.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.